Document Detail

Epidermal growth factor accelerates pancreatic recovery after caerulein-induced pancreatitis.
MedLine Citation:
PMID:  10856460     Owner:  NLM     Status:  MEDLINE    
We examined the influence of endogenous and exogenous epidermal growth factor (EGF) on pancreatic repair after acute pancreatitis. Caerulein-induced pancreatitis was evoked in rats with intact or removed salivary glands and EGF (10 microg/kg) was administered starting 24 h after cessation of caerulein infusion. The dose of EGF 10 microg/kg was chosen because it was the most effective in preliminary experiments when 1, 10 or 50 microg/kg of EGF was used. Caerulein administration caused acute edematous pancreatitis with biochemical and histological manifestation of pancreatic damage, followed by spontaneous regeneration. The effect of salivectomy on the course of acute pancreatitis was slight, resulting in additional reduction in pancreatic blood flow, DNA synthesis and in an increase in plasma interleukin 1beta level. Treatment with EGF accelerated the healing of pancreatic damage, causing an increase in pancreatic blood flow and DNA synthesis. EGF caused faster normalization of plasma amylase and lipase activity and plasma interleukin 1beta concentration, as well as, this peptide accelerated the restoration of pancreatic amylase activity. On histological examination, EGF caused reduction of pancreatic damage and acceleration of tissue repair. We conclude that EGF reduces the severity of pancreatic damage evoked by caerulein-induced pancreatitis-related pancreatic damage and accelerates tissue repair. The beneficial effects of EGF appear to depend, at least in part, on the improvement of pancreatic blood flow, as well as on an increase of pancreatic cell growth and limitation of the activation cytokine release.
A Dembiński; Z Warzecha; P C Konturek; P Ceranowicz; J Stachura; R Tomaszewska; S J Konturek
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  European journal of pharmacology     Volume:  398     ISSN:  0014-2999     ISO Abbreviation:  Eur. J. Pharmacol.     Publication Date:  2000 Jun 
Date Detail:
Created Date:  2000-08-10     Completed Date:  2000-08-10     Revised Date:  2004-11-17    
Medline Journal Info:
Nlm Unique ID:  1254354     Medline TA:  Eur J Pharmacol     Country:  NETHERLANDS    
Other Details:
Languages:  eng     Pagination:  159-68     Citation Subset:  IM    
Department of Physiology, Collegium Medicum, Jagiellonian University, 16 Grzegórzecka street, 31-531, Kraków, Poland.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Amylases / blood,  drug effects
DNA / biosynthesis,  drug effects
Dose-Response Relationship, Drug
Epidermal Growth Factor / pharmacology*
Interleukin-1 / blood
Lipase / blood,  drug effects
Organ Size / drug effects
Pancreas / blood supply,  drug effects*,  pathology
Pancreatitis / chemically induced,  enzymology,  prevention & control*
RNA / drug effects,  metabolism
Rats, Wistar
Regional Blood Flow / drug effects
Time Factors
Reg. No./Substance:
0/Interleukin-1; 17650-98-5/Caerulein; 62229-50-9/Epidermal Growth Factor; 63231-63-0/RNA; 9007-49-2/DNA; EC; EC 3.2.1.-/Amylases

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Role of gastric acid secretion in progression of acute gastric erosions induced by ischemia-reperfus...
Next Document:  Effects of low-dose VOSO(4) on age-related changes in glucose homeostasis in rats.